We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal.
|
Status
|
Suspended
|
|
Decision
|
Selected
|
| Process |
STA pre-2018
|
| ID number |
1002
|
Project Team
Email enquiries
Stakeholders
| Companies sponsors |
Janssen (sirukumab) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Arthritis Action |
| |
National Rheumatoid Arthritis Society |
| Professional groups |
British Society for Rheumatology |
| |
Primary Care Rheumatology Society |
| |
Royal College of Physicians |
| |
UK Clinical Pharmacy Association |
| Comparator companies |
AbbVie |
| |
Accord Healthcare - (CAU not returned, not participating) |
| |
Amdipharm Mercury - (CAU not returned, not participating) |
| |
Biogen |
| |
Bristol-Myers Squibb |
| |
Concordia international - (CAU not returned, not participating) |
| |
Eli Lilly |
| |
Hameln pharmaceuticals - (CAU not returned, not participating) |
| |
Hospira - (CAU not returned, not participating) |
| |
medac - (CAU not returned, not participating) |
| |
Merck Sharp & Dohme |
| |
Napp |
| |
Nordic Pharma - (CAU not returned, not participating) |
| |
Orion Pharma - (CAU not returned, not participating) |
| |
Pfizer |
| |
Roche |
| |
Rosemont Pharmaceuticals - (CAU not returned, not participating) |
| |
Sandoz - (CAU not returned, not participating) |
| |
UCB Pharma Limited |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Welsh Health Specialised Services Committee |